Periodic Reporting for period 1 - EuroNanoMed III (ERA-NET ON NANOMEDICINE) Reporting period: 2016-11-01 to 2017-10-31 Summary of the context and overall objectives of the project Nanomedicine is the application of nanotechnology to medicine and healthcare. The field takes advantage of the physical, chemical and biological properties of materials at the nanometer scale to be used for a better understanding of the biological mechanisms of diseases at the molecular level, leading to new targets for earlier and more precise diagnostics and therapeutics. Nanomedicine, rated among the six most promising Key Enabling Technologies, is one of the most important emerging areas of health research expected to contribute to one of the strategic challenges that Europe has to face in the future: Provide effective and affordable health care and assure the wellbeing of an increasingly aged population.EuroNanoMed III (ENM III) builds on the foundations of ENM I & II, which launched 7 successful joint calls for proposals since 2009, funded 51 transnational research projects involving 269 partners from 25 countries/regions, and allocated € 45,5 million to research projects from ENM funding agencies. ENM III consortium, reinforced with 12 new partners from Europe, Canada and Taiwan, is committed to fostering the competiveness of European nanomedicine actors taking into account recent changes in the landscape and new stakeholders and challenges, as identified in the SRIA in nanomedicine. The first joint call for proposals will be co-funded by ENM III partners and the EC. After the co-funded call, three additional joint transnational calls will be organized and strategic activities will be accomplished in collaboration with key initiatives in the field. ENM III actions focus on translatability of project results to clinical and industry needs. Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far In response to the 8th Joint Transnational Call 2017, 126 eligible pre-proposals involving 588 groups from 20 different countries were submitted. After the first evaluation step, 39 proposals were invited to the second stage. Following the recommendations of the Peer Review Panel, the funding organisations participating in the EuroNanoMed cofunded call were able to fund the following 16 innovative research projects in Nanomedicine. Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far) The main achievements so far in addition to the outcomes of the co-funded call and the launching of the Joint Transnational Call 2018 is the development, publication and call implementation of the RRI Guidelines.
